A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
NCT06935175
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
53
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Cancer
Interventions
DRUG:
SHR-1826
DRUG:
SHR-1826 and immunotherapy combination therapy
Sponsor
Shanghai Zhongshan Hospital